Acton, MA, United States of America

Klaus Charisse

USPTO Granted Patents = 42 

 

 

Average Co-Inventor Count = 7.7

ph-index = 8

Forward Citations = 265(Granted Patents)


Location History:

  • Cambridge, MA (US) (2015 - 2024)
  • Acton, MA (US) (2015 - 2024)

Company Filing History:


Years Active: 2015-2025

Loading Chart...
Loading Chart...
Loading Chart...
42 patents (USPTO):Explore Patents

As an AI assistant specializing in innovations, inventions, inventors, patent attorneys, assignees, and patents, I'm here to assist you in creating an article about inventor Klaus Charisse. Here is the structured article based on the information provided:

Title:

Inventor Spotlight: Klaus Charisse - Pioneering RNAi Innovations

Introduction:

Klaus Charisse, a prolific inventor based in Acton, MA (US), has made significant contributions to the field of RNA interference (RNAi) with an impressive portfolio of 36 patents. Let's delve into his latest patents, career highlights, and collaborations that have shaped his innovative journey.

Latest Patents:

Klaus Charisse's recent patents include groundbreaking inventions in the realm of RNAi therapeutics:

1. SERPINA1 iRNA compositions and methods of use thereof: This patent focuses on RNAi agents targeting the Serpina1 gene, offering promising methods to treat Serpina1-associated diseases like liver disorders.

2. Complement component C5 iRNA compositions and methods of use thereof: Charisse's innovative work involves iRNA compositions targeting the complement component C5 gene, showcasing potential treatment methods for diseases such as paroxysmal nocturnal hemoglobinuria.

Career Highlights:

Klaus Charisse is associated with Alnylam Pharmaceuticals, Inc., a leading biopharmaceutical company at the forefront of RNAi therapeutics development. His role at Alnylam has been instrumental in driving forward innovative solutions in the field of genetic medicine.

Collaborations:

Collaborating with esteemed colleagues like Martin A Maier and Kallanthottathil G Rajeev, Klaus Charisse has fostered a dynamic environment for cutting-edge research and development in RNAi technologies. These collaborations have amplified the impact of his inventions in the scientific community.

Conclusion:

In conclusion, Klaus Charisse's pioneering work in RNAi technologies exemplifies a commitment to innovation and healthcare advancement. With a remarkable patent portfolio and strategic collaborations, Charisse continues to shape the landscape of genetic medicine, offering new hope for patients with complex genetic disorders.

If you need further assistance or more information on inventors, patent applications, and innovations, feel free to ask.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…